Success Metrics

Clinical Success Rate

81.8%

Based on 9 completed trials

Completion Rate

82%(9/11)

Active Trials

7(35%)

Results Posted

11%(1 trials)

Terminated

2(10%)

Phase Distribution

Ph phase_1

15%

Ph early_phase_1

Ph not_applicable

10%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Early Phase 1First-in-human

1(16.7%)

Phase 1Safety & dosage

3(50.0%)

N/ANon-phased studies

2(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(8)

Completed(9)

Terminated(2)

Other(1)

Detailed Status

Completed9

Recruiting4

Active, not recruiting3

Terminated2

Enrolling by invitation1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

81.8%

Most Advanced

Phase 1

Trials by Phase

Early Phase 11 (16.7%)

Phase 13 (50.0%)

N/A2 (33.3%)

Trials by Status

enrolling_by_invitation15%

active_not_recruiting315%

recruiting420%

terminated210%

unknown15%

completed945%

Recent Activity

7 active trials

Showing 5 of 20

recruitingphase_1

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT07025538

completed

Clinical Trials (20)

Showing 20 of 20 trials

NCT07025538Phase 1

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

Recruiting

NCT01822444

ANGIOPREDICT. ICORG 12-16, V3

Completed

NCT04435756

A Study of miRNA 371 in Patients With Germ Cell Tumors

Active Not Recruiting

NCT04717869

Identifying Modifiable PAtient Centered Therapeutics (IMPACT) Frailty

Recruiting

NCT02897427

Throat and Other HPV-Related Cancers in Men: Identifying Them Early

Active Not Recruiting

NCT07100054

Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors

Enrolling By Invitation

NCT07063758

A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma

Active Not Recruiting

NCT01840306

Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer

Completed

NCT06875336

A Multicentric Cohort and Biomarker Study for Improved Care of Patients with Extrapulmonary Tuberculosis

Recruiting

NCT03779867Not Applicable

Acute Exercise Intervention in Breast Cancer Survivors

Terminated

NCT02809716

High Definition Single Cell Analysis in Colorectal Cancer

Completed

NCT02457910Phase 1

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Terminated

NCT04914026

MicroRNA as Markers in Testicular Cancer

Recruiting

NCT04997876

Diagnostic Reliability of OCT Biomarkers for iERM

Completed

NCT04202055

Immunologic Biomarker Profile of Cerebrospinal Fluid

Completed

NCT01975363Not Applicable

Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer

Completed

NCT02204943Early Phase 1

Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer

Completed

NCT00753207Phase 1

Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30

Completed

NCT00897338

Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer

Completed

NCT00553371

Follow-up Evaluation Using CT Scans in Patients Who Have Been Treated For Metastatic Testicular Cancer

Unknown

All 20 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 20